This controversy has escalated recently with the approval of adjuvant abemaciclib by the FDA for patients with high-risk HR + HER2 + BC based on the Ki67 selection criteria [25], highlighting reproducibility as one of the limitations when Ki67 is used on a widespread basis. Here, ERBB2 is linked to breast cancer.